Details
| Product Infomation | |
|---|---|
| Product Description: | CD Thyroid Cancer Mutation Panel provides reagents for detection of point mutations in BRAF and RAS genes, as well as RET/PTC1,3 and PAX8/PPARg fusion gene variants. The assay is performed in two runs; one run is performed for detection of point mutations in BRAF and RAS genes using genomic DNA as the input, and the other is performed for detection of the fusion genes using total cellular RNA. Fusion detection reactions are done using a one-step enzyme mix that combines cDNA synthesis and qPCR into a single step. The assay is optimized for use with nucleic acids isolated from FFPE, FNA and frozen tissues.Thyroid cancer is the most common endocrine malignancy in the United States. Recent studies have identified two types of genetic alterations in thyroid cancer; point mutations in BRAF, KRAS, NRAS, or HRAS, and chromosomal translocations involving RET/PTC1, RET/PTC3, or PAX8/PPARg. Detection of these genetic markers enables definitive diagnosis of malignant tumors that are distinct from more commonly occurring thyroid nodules, which are considered to be benign. |
| Features: | Works with FFPE, fresh frozen and FNA samples. Simple setup and interpretation. Requires DNA & RNA. Includes control standards. |
| Storage: | Store in <-20°C freezer. Repeated thawing and freezing should be avoided. |
| Method: | Real-Time Qualitative PCR |
| Equipment Required: | The Thyroid Cancer Mutation Panel requires a real-time PCR instrument capable of detecting FAM and VIC fluorescent probes. This kit includes primer/probe mix for detection of all mutations listed above, enzyme mix, and validated control standards. |
Please submit a detailed description of your project. We will provide you with a customized project plan to meet your research requests. You can also send emails directly to for inquiries.
Please fill out the form below: ×
